Back to top
more

Takeda Pharmaceutical Co. (TAK)

(Delayed Data from NYSE)

$13.17 USD

13.17
1,333,129

+0.14 (1.07%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $13.17 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

General Information

Takeda Pharmaceutical Co

1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU

TOKYO, M0 103-8668

Phone: 813-3278-2111

Fax: 813-3278-2268

Web: http://www.takeda.com

Email: takeda.ir.contact@takeda.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End March
Last Reported Quarter 3/31/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/9/2024

EPS Information

Current Quarter EPS Consensus Estimate NA
Current Year EPS Consensus Estimate 1.50
Estimated Long-Term EPS Growth Rate 2.80
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/9/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 13.03
52 Week High 17.12
52 Week Low 13.01
Beta 0.53
20 Day Moving Average 1,749,156.38
Target Price Consensus 17.17

TAK

% Price Change
4 Week -6.19
12 Week -8.75
YTD -8.69
% Price Change Relative to S&P 500
4 Week -3.35
12 Week -11.28
YTD -14.60
Share Information
Shares Outstanding (millions) 3,164.84
Market Capitalization (millions) 41,237.83
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 4.01%
Annual Dividend $0.52
Payout Ratio 0.27
Change in Payout Ratio -0.05
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 8.41
Trailing 12 Months 6.68
PEG Ratio 2.97
EPS Growth
vs. Previous Year 10.87%
vs. Previous Quarter 2.00%
   
Sales Growth
vs. Previous Year -10.38%
vs. Previous Quarter 8.48%
   
Price Ratios
Price/Book 0.90
Price/Cash Flow 3.63
Price / Sales 1.40
ROE
3/31/24 NA
12/31/23 12.57
9/30/23 12.36
ROA
3/31/24 NA
12/31/23 5.89
9/30/23 5.74
Current Ratio
3/31/24 NA
12/31/23 1.06
9/30/23 1.04
Quick Ratio
3/31/24 NA
12/31/23 0.55
9/30/23 0.55
Operating Margin
3/31/24 NA
12/31/23 20.55
9/30/23 19.41
Net Margin
3/31/24 NA
12/31/23 6.90
9/30/23 7.35
Pre-Tax Margin
3/31/24 NA
12/31/23 3.72
9/30/23 4.75
Book Value
3/31/24 NA
12/31/23 14.49
9/30/23 15.42
Inventory Turnover
3/31/24 NA
12/31/23 1.24
9/30/23 1.27
Debt-to-Equity
3/31/24 NA
12/31/23 0.64
9/30/23 0.62
Debt to Capital
3/31/24 NA
12/31/23 38.91
9/30/23 38.38